Biotech | May 26, 2026
Genethon and Ampersand team up to engineer next-gen gene therapy vectors with precision
AAV vectors are widely used in gene therapy for their strong therapeutic potential
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The decision marks a key step in the centralized EU review process
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
With standout ADC and t-cell engager response data across hard-to-treat cancers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
